{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:47:17Z","timestamp":1782935237265,"version":"3.54.5"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ihj.2023.11.004","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:49:55Z","timestamp":1700254195000},"page":"S58-S64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Management of triglycerides, non-high density lipoprotein cholesterol and high density lipoprotein cholesterol"],"prefix":"10.1016","volume":"76","author":[{"given":"Geevar","family":"Zachariah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ihj.2023.11.004_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2023.11.004_bib2","doi-asserted-by":"crossref","first-page":"m3109","DOI":"10.1136\/bmj.m3109","article-title":"Management of hypertriglyceridemia","volume":"371","author":"Simha","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ihj.2023.11.004_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.ihj.2023.11.004_bib4","first-page":"663","article-title":"HDL cholesterol: reappraisal of its clinical relevance","volume":"106","author":"M\u00e4rz","year":"2017","journal-title":"Clin Res Cardiol Off J Ger Card Soc"},{"issue":"5","key":"10.1016\/j.ihj.2023.11.004_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ihj.2022.07.009","article-title":"Guidelines for dyslipidemia management in India: a review of the current scenario and gaps in research","volume":"74","author":"Misra","year":"2022","journal-title":"Indian Heart J"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.004_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.4103\/2230-8210.122600","article-title":"Atherogenic dyslipidemia","volume":"17","author":"Manjunath","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.004_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacl.2008.10.005","article-title":"Population variations in atherogenic dyslipidemia: a report from the HeartSCORE and IndiaSCORE Studies","volume":"2","author":"Mulukutla","year":"2008","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.ihj.2023.11.004_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096808","article-title":"Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study","volume":"9","author":"Joshi","year":"2014","journal-title":"PLoS One"},{"issue":"49","key":"10.1016\/j.ihj.2023.11.004_bib9","first-page":"825","article-title":"The diagnosis and treatment of hypertriglyceridemia","volume":"116","author":"Parhofer","year":"2019","journal-title":"Dtsch Arzteblatt Int"},{"issue":"25","key":"10.1016\/j.ihj.2023.11.004_bib10","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.ihj.2023.11.004_bib11","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ihj.2023.11.004_bib12","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"39","key":"10.1016\/j.ihj.2023.11.004_bib13","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2023.11.004_bib14","series-title":"Hypertriglyceridemia In Adults: Approach To Evaluation","author":"Rosenson","year":"2023"},{"issue":"1","key":"10.1016\/j.ihj.2023.11.004_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jacl.2018.11.008","article-title":"Hypertriglyceridemia in statin-treated US adults: the national health and nutrition examination survey","volume":"13","author":"Fan","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.ihj.2023.11.004_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1464-5491.2011.03360.x","article-title":"Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study","volume":"28","author":"Leiter","year":"2011","journal-title":"Diabet Med J Br Diabet Assoc"},{"issue":"7","key":"10.1016\/j.ihj.2023.11.004_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"10.1016\/j.ihj.2023.11.004_bib18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jacc.2017.08.006","article-title":"A test in context: lipid profile, fasting versus nonfasting","volume":"70","author":"Nordestgaard","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ihj.2023.11.004_bib19","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1161\/ATVBAHA.108.169383","article-title":"Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans","volume":"28","author":"Pavlic","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.004_bib20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2265.2011.04328.x","article-title":"Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study","volume":"76","author":"Waring","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ihj.2023.11.004_bib21","unstructured":"Rosenson RS, Eckel RH. Hypertriglyceridemia in Adults: Management. In:UpToDate, Freeman MW, Parikh N, Givens J (Ed), UpToDate, Waltham, MA. (Accessed on March 06, 2022.). In."},{"issue":"9","key":"10.1016\/j.ihj.2023.11.004_bib22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American college of cardiology solution set oversight committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ihj.2023.11.004_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/archinte.159.9.981","article-title":"Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state","volume":"159","author":"Pownall","year":"1999","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.004_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.arcmed.2017.11.017","article-title":"Optimizing non-pharmacologic management of hypertriglyceridemia","volume":"48","author":"Byrne","year":"2017","journal-title":"Arch Med Res"},{"issue":"25 Pt B","key":"10.1016\/j.ihj.2023.11.004_bib25","first-page":"2985","article-title":"AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines and the obesity society","volume":"63","author":"Jensen","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"25 Suppl 2","key":"10.1016\/j.ihj.2023.11.004_bib26","first-page":"S76","article-title":"AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"129","author":"Eckel","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2023.11.004_bib27","series-title":"Encyclopedia of Endocrine Diseases","article-title":"Dyslipidemia in diabetes","author":"Subramanian","year":"2019"},{"issue":"9","key":"10.1016\/j.ihj.2023.11.004_bib28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","article-title":"A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia","volume":"117","author":"Karlson","year":"2016","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.ihj.2023.11.004_bib29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.ihj.2023.11.004_bib30","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ihj.2023.11.004_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","article-title":"Clinical pharmacokinetics of fibric acid derivatives (fibrates)","volume":"34","author":"Miller","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"19","key":"10.1016\/j.ihj.2023.11.004_bib32","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1001\/archinte.163.19.2394","article-title":"Possible differences between fibrates in pharmacokinetic interactions with statins","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.004_bib33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ihj.2023.11.004_bib34","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"9729","key":"10.1016\/j.ihj.2023.11.004_bib35","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ihj.2023.11.004_bib36","article-title":"Efficacy and safety of K-877 (pemafibrate), a selective PPAR\u03b1 modulator","volume":"vol. 45","author":"Ginsberg","year":"2022"},{"issue":"21","key":"10.1016\/j.ihj.2023.11.004_bib37","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ihj.2023.11.004_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ihj.2023.11.004_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/DMSO.S49592","article-title":"Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence","volume":"8","author":"Sosale","year":"2015","journal-title":"Diabetes, Metab Syndrome Obes Targets Ther"},{"issue":"7","key":"10.1016\/j.ihj.2023.11.004_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100233","article-title":"Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial","volume":"63","author":"Rodriguez-Gutierrez","year":"2022","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.ihj.2023.11.004_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13841","article-title":"Volanesorsen to treat severe hypertriglyceridaemia: a pooled analysis of randomized controlled trials","volume":"52","author":"Calcaterra","year":"2022","journal-title":"Eur J Clin Invest"},{"issue":"21","key":"10.1016\/j.ihj.2023.11.004_bib42","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.118.034273","article-title":"Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease","volume":"138","author":"Abdullah","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ihj.2023.11.004_bib43","first-page":"148","article-title":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment","volume":"51","author":"Carr","year":"2019","journal-title":"Pathology (Phila)."},{"issue":"3","key":"10.1016\/j.ihj.2023.11.004_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10215","key":"10.1016\/j.ihj.2023.11.004_bib45","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","article-title":"Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium","volume":"394","author":"Brunner","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.004_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10408363.2013.847897","article-title":"ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management","volume":"50","author":"de Nijs","year":"2013","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"11","key":"10.1016\/j.ihj.2023.11.004_bib47","first-page":"8","article-title":"Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2020: Part III","volume":"68","author":"Puri","year":"2020","journal-title":"J Assoc Phys India"},{"issue":"1","key":"10.1016\/j.ihj.2023.11.004_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/03014460.2012.744094","article-title":"The association of non-HDL cholesterol with the presence of metabolic syndrome in North Indian subjects with and without CAD","volume":"40","author":"Garg","year":"2013","journal-title":"Ann Hum Biol"},{"issue":"3","key":"10.1016\/j.ihj.2023.11.004_bib49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12291-018-0758-6","article-title":"Non-HDL as a valid surrogate marker of small dense LDL in a young Indian population","volume":"34","author":"Manocha","year":"2019","journal-title":"Indian J Clin Biochem IJCB"},{"issue":"3","key":"10.1016\/j.ihj.2023.11.004_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ihj.2020.05.008","article-title":"Is evaluation of non-HDL-C better than calculated LDL-C in CAD patients? MMIMSR experiences","volume":"72","author":"Kathariya","year":"2020","journal-title":"Indian Heart J"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.004_bib51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ihj.2023.11.004_bib52","doi-asserted-by":"crossref","first-page":"g4356","DOI":"10.1136\/bmj.g4356","article-title":"Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ihj.2023.11.004_bib53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-019-1080-x","article-title":"Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol","volume":"18","author":"Su","year":"2019","journal-title":"Lipids Health Dis"},{"issue":"18","key":"10.1016\/j.ihj.2023.11.004_bib54","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.ihj.2023.11.004_bib55","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ihj.2023.11.004_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ihj.2023.11.004_bib57","unstructured":"Rosenson RS, Durrington P. HDL Cholesterol: Clinical Aspects of Abnormal Values. In:UpToDate, Freeman MW, Givens J, Parikh N (Ed), UpToDate, Waltham, MA. (Accessed on March 06, 2022. In."},{"issue":"9634","key":"10.1016\/j.ihj.2023.11.004_bib58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ihj.2023.11.004_bib59","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.ihj.2023.11.004_bib60","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ihj.2023.11.004_bib61","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ihj.2023.11.004_bib62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/CIRCRESAHA.116.308685","article-title":"Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity","volume":"119","author":"Didichenko","year":"2016","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.ihj.2023.11.004_bib63","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ihj.2023.11.004_bib64","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.amjcard.2010.12.015","article-title":"Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study)","volume":"107","author":"Rahilly-Tierney","year":"2011","journal-title":"Am J Cardiol"},{"issue":"22","key":"10.1016\/j.ihj.2023.11.004_bib65","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483223001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483223001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T01:38:08Z","timestamp":1712626688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483223001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":65,"alternative-id":["S0019483223001773"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2023.11.004","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of triglycerides, non-high density lipoprotein cholesterol and high density lipoprotein cholesterol","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2023.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}